A Phase I Trial of the Intravenous Hsp90 Inhibitor alvespimycin (17-DMAG) in Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Ítems similars

• 17-DMAG targets the nuclear factor-κB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition
  per: Hertlein, Erin, et al.
  Publicat: (2010)
• Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia
  per: Chen, Timothy L., et al.
  Publicat: (2016)
• A Phase I study of the Heat Shock Protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors
  per: Pacey, Simon, et al.
  Publicat: (2011)
• A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia()
  per: Maddocks, Kami, et al.
  Publicat: (2014)
• The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma
  per: Hu, Yafang, et al.
  Publicat: (2015)